Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

359 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease.
Numajiri H, Yoshizaki A, Fukasawa T, Ebata S, Nakamura K, Yamashita T, Saigusa R, Miura S, Hirabayashi M, Yoshizaki A, Sumida H, Asano Y, Kazoe Y, Mawatari K, Kitamori T, Sato S. Numajiri H, et al. Among authors: fukasawa t. J Dermatol. 2018 Oct;45(10):1221-1224. doi: 10.1111/1346-8138.14580. Epub 2018 Jul 27. J Dermatol. 2018. PMID: 30051925
Combination therapy for hypertension in patients with CKD: a subanalysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events trial.
Rakugi H, Ogihara T, Umemoto S, Matsuzaki M, Matsuoka H, Shimada K, Higaki J, Ito S, Kamiya A, Suzuki H, Ohashi Y, Shimamoto K, Saruta T; Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Rakugi H, et al. Hypertens Res. 2013 Nov;36(11):947-58. doi: 10.1038/hr.2013.63. Epub 2013 Jul 18. Hypertens Res. 2013. PMID: 23864054 Clinical Trial.
Nucleosome in patients with systemic sclerosis: possible association with immunological abnormalities via abnormal activation of T and B cells.
Yoshizaki A, Taniguchi T, Saigusa R, Fukasawa T, Ebata S, Numajiri H, Nakamura K, Yamashita T, Takahashi T, Toyama T, Asano Y, Tedder TF, Sato S. Yoshizaki A, et al. Among authors: fukasawa t. Ann Rheum Dis. 2016 Oct;75(10):1858-65. doi: 10.1136/annrheumdis-2015-207405. Epub 2015 Nov 13. Ann Rheum Dis. 2016. PMID: 26567180
Unprecedented success of rituximab therapy for prednisolone- and immunosuppressant-resistant systemic sclerosis-associated interstitial lung disease.
Ebata S, Yoshizaki A, Fukasawa T, Nakamura K, Yamashita T, Miura S, Saigusa R, Ichimura Y, Takahashi T, Hirabayashi M, Taniguchi T, Akamata K, Asano Y, Sato S. Ebata S, et al. Among authors: fukasawa t. Scand J Rheumatol. 2017 May;46(3):247-252. doi: 10.1080/03009742.2016.1231341. Epub 2016 Nov 30. Scand J Rheumatol. 2017. PMID: 27900875 No abstract available.
Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis.
Fukasawa T, Yoshizaki A, Ebata S, Nakamura K, Saigusa R, Miura S, Yamashita T, Hirabayashi M, Ichimura Y, Taniguchi T, Asano Y, Shimizu H, Kazoe Y, Mawatari K, Kitamori T, Sato S. Fukasawa T, et al. Arthritis Rheumatol. 2017 Sep;69(9):1879-1890. doi: 10.1002/art.40164. Epub 2017 Aug 1. Arthritis Rheumatol. 2017. PMID: 28556548
Exacerbated Immune Complex-Mediated Vascular Injury in Mice with Heterozygous Deficiency of Aryl Hydrocarbon Receptor through Upregulation of Fcγ Receptor III Expression on Macrophages.
Nakajima R, Miyagaki T, Morimura S, Fukasawa T, Oka T, Yoshizaki A, Sugaya M, Sato S. Nakajima R, et al. Among authors: fukasawa t. J Invest Dermatol. 2018 Oct;138(10):2195-2204. doi: 10.1016/j.jid.2018.03.1520. Epub 2018 Mar 30. J Invest Dermatol. 2018. PMID: 29605671 Free article.
359 results